| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | CCT018159 | GDSC1000 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | KIN001-266 | GDSC1000 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | AGK-2 | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | S-Trityl-L-cysteine | FIMM | pan-cancer | AAC | 0.018 | 0.9 |
| mRNA | 3-Cl-AHPC | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |